Venmax Drugs and Pharmaceuticals MD, chairman, board of directors and AGM
BSE: 531015Pharmaceuticals & BiotechnologySmall Cap
Share price at the BSE close on 23 Oct 2026. Previous close ₹14.99.
- Under BSE's graded surveillance, stage 0, on the list for 22 Oct 2026. The exchange puts a share here when its price has moved unusually, and trading in it carries extra conditions.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹17 Cr4,053rd largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit.
- Earlier quarters restated in the year
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Not shown: another business merged into the company on 30 Jun 2026, and the accounts this figure is made of do not include it yet. It returns once accounts of the company as it now is are filed.
- Mergernew accounts awaited
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- Volume, BSEVolume. Shares traded on the last trading day.
- 7,037
Venmax Drugs and Pharmaceuticals board of directors
At the end of the quarter to Sep 2026, as the company filed it; changes since are in its announcements.
- Chairperson and managing directorVenkata Rao Sadhanala
- Company Secretary and Compliance OfficerPriyanka Agarwal
6 directors2 independent1 executive3 non-executive
- Venkata Rao Sadhanala · Chairperson and managing directorExecutive · joined Oct 2024 · 3 listed boards · 1 committee seat, 1 as chair
- Swapneswar MishraNon-executive · joined Jan 2024 · reappointed Sep 2026 · 1 listed board · 1 committee seat, 1 as chair
- Dasi Reddy RakeshNon-executive · joined Aug 2024 · 2 listed boards · 2 committee seats
- Gundluru ReddeppaIndependent · joined Aug 2024 · 60 months as independent · 2 listed boards · 2 as independent · 3 committee seats, 1 as chair
- Revoor RamachandraIndependent · joined Mar 2026 · 60 months as independent · 2 listed boards · 2 as independent · 2 committee seats
- Padmaja kalyani SadhanalaNon-executive · joined Mar 2026 · 1 listed board
An independent director has no business or family tie to the company, its promoters or its managers beyond the seat. Listed boards counts the boards of listed companies the director sits on, this one included, and "as independent" how many of those seats are independent ones. Committee seats are audit and stakeholder committee seats across those companies. Months as independent is filed for independent directors only, whose terms the rules cap. Disqualified is the company's own mark that a director may not serve under company law.
Committees and meetings
Who sits on each, and how often they met.Board meeting notices and outcomes
Board
- 31 Aug 20266 of 6 present6 independent · 23 days in between
- 7 Aug 20266 of 6 present6 independent · 7 days in between
- 30 Jul 20266 of 6 present6 independent · no day in between
- 29 Jul 20266 of 6 present6 independent · 75 days in between
1 earlier meeting
- 14 May 20266 of 6 present6 independent
Audit Committee
Chair Gundluru Reddeppa
Revoor Ramachandra, Swapneswar Mishra
- 7 Aug 20263 of 3 present2 independent · 84 days in between
- 14 May 20263 of 3 present2 independent
Nomination and remuneration committee
Chair Gundluru Reddeppa
Dasi Reddy Rakesh, Revoor Ramachandra
No meeting listed in the filing.
Stakeholders Relationship Committee
Chair Swapneswar Mishra
Gundluru Reddeppa, Dasi Reddy Rakesh
No meeting listed in the filing.
Meetings in the quarter filed and the one before it. The days in between are as the company files them, neither meeting's day counted; the rules allow at most 120. A quorum is the least number of members who must attend for the meeting to decide anything.
Statutory auditor
Named in the results for the quarter to Mar 2026.
- PPKG&COPeer-review certificate valid to Jan 2029
1 earlier auditor
- PPKG & CONamed in the filing for the quarter to Mar 2025
A statutory auditor checks the company's accounts and signs its results. Peer review is the accountants' institute's check of an audit firm's own work, which a listed company's auditor must hold a valid certificate of.
Venmax Drugs and Pharmaceuticals AGM and shareholder votes
Each resolution, how the votes went, and how institutions voted apart from the promoters. A postal ballot is a vote by post or online, held without a meeting.Venmax Drugs and Pharmaceuticals share news and announcements
Annual general meeting, 26 Sep 2026
6,980 shareholders on the register on 18 Sep 2026; present: 0 promoters and 45 others; votes counted by Mr. Kashinath Sahu / M/s. Kashinath Sahu & Co.The company's voting result (opens in a new tab)
- Adoption of the Audited Standalone Financial Statements of the Company for the Financial Year ended 31st March, 2026 and the Reports of the Auditors and Board of Directors thereonOrdinary95.73% for4.27% against
Against: promoters 0.00% · institutions 0.00% · other public 4.98%
Turnout: all 55.65% · promoters 76.46% · institutions 0.00% · other public 53.22%
- Appointment of a Director in place of Mr. Swapneswar Mishra (DIN: 09594775), who retires by rotation and being eligible offers himself for re-appointmentOrdinary95.73% for4.27% against
Against: promoters 0.00% · institutions 0.00% · other public 4.99%
Turnout: all 55.65% · promoters 76.46% · institutions 0.00% · other public 53.22%
- Approval of Change in designation of Mr. Venkata Rao Sadhanala, (DIN: 02906370) from Whole Time Director to Managing Director of the CompanySpecial95.73% for4.27% against
Against: promoters 0.00% · institutions 0.00% · other public 4.99%
Turnout: all 55.65% · promoters 76.46% · institutions 0.00% · other public 53.22%
- Regularization of Mrs. Padmaja Kalyani Sadhanala (DIN:03096445), Additional Director as Non-Executive Non-Independent Director of the CompanyOrdinary95.73% for4.27% against
Against: promoters 0.00% · institutions 0.00% · other public 4.99%
Turnout: all 55.65% · promoters 76.46% · institutions 0.00% · other public 53.22%
- Regularization of Appointment of Mr. Revoor Ramachandra (DIN: 00490051), Additional Director as Non-Executive Independent Director of the CompanySpecial95.73% for4.27% against
Against: promoters 0.00% · institutions 0.00% · other public 4.99%
Turnout: all 55.65% · promoters 76.46% · institutions 0.00% · other public 53.22%
For and against are per cent of the votes cast. Turnout is the votes cast as a per cent of the shares each group holds. Institutions are funds, insurers, banks and foreign investors. An ordinary resolution passes with more than half the votes cast, a special one with at least three quarters.
Investor complaints and compliance
Quarter by quarter.
Investor complaints received and resolved, the company's own count
- Received
- Resolved
Open at the quarter's end
- The board is made up as the listing rules require
- Yes
- The board has a regular chairperson
- No
- The company has a risk management committee
- No
- The chair is related to the managing director
- No
- The filing has a part on fines and penalties
- No
- The filing has a part on tax disputes
- No
- There was a cyber security incident in the quarter
- No
The company's own answers in its filing.
How money raised was used
Reported for the quarter to Dec 2025. The company's results filing for the quarter to Jun 2026 says no statement of how money raised was used applies to it. A preferential issue sells new shares to chosen investors rather than to the public. A warrant or partly paid issue plans the whole issue while the money comes in over time, so the amount set aside can be more than raised so far.
| Raised | Amount raised | For | Set aside | Spent | Spent elsewhere |
|---|---|---|---|---|---|
| Preferential IssuesMar 2025 | 20.05 | Working Capital | 10.00 | 3.79 | No |
| Preferential IssuesMar 2025 | 20.05 | 0 | 10.05 | 0.19 | No |